Esperion Therapeutics Inc
NASDAQ:ESPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Esperion Therapeutics Inc
Gross Profit
Esperion Therapeutics Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Esperion Therapeutics Inc
NASDAQ:ESPR
|
Gross Profit
$273.9m
|
CAGR 3-Years
78%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$65.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$35B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$47.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$53B
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$54.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
23%
|
CAGR 10-Years
14%
|
|
Esperion Therapeutics Inc
Glance View
Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 218 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
See Also
What is Esperion Therapeutics Inc's Gross Profit?
Gross Profit
273.9m
USD
Based on the financial report for Dec 31, 2025, Esperion Therapeutics Inc's Gross Profit amounts to 273.9m USD.
What is Esperion Therapeutics Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
4%
Over the last year, the Gross Profit growth was 4%. The average annual Gross Profit growth rates for Esperion Therapeutics Inc have been 78% over the past three years , 4% over the past five years .
